Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Conclusions: After accounting for differences in baseline characteristics and adherence, patients treated with alirocumab who achieved LDL-C levels <25 mg/dL did not appear to derive further reduction in the risk of MACE compared to those who achieved LDL-C levels of 25-50 mg/dL. Clinical Trial Registration: URL: https://www.clinicaltrials.gov Unique identifier: NCT01663402.
PMID: 33438437 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, ODYSSEY OUTCOMES Committees and Investigators Tags: Circulation Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Coronary Heart Disease | Heart | Heart Attack | Heart Disease | Ischemic Stroke | Laboratory Medicine | Statin Therapy | Stroke | Study